What’s next for M&A? Precision medicine, diagnostics, new customers to disrupt pharma services market
Increasingly complex clinical trials are putting pressure on CROs to expand their service offerings in what has been a historically monolithic space – with diagnostics also continuing to play a more important role in the market, says industry expert.
